Novo Nordisk Annual Report 2021
Contents
Introducing Novo Nordisk
Strategic Aspirations
Key risks Management
Consolidated statements
Additional information
Novo Nordisk Annual Report 2021
57
Net sales - Business segments and geographical areas
Total International Operations
Total North America Operations
Total Novo Nordisk
net sales
Total IO
EMEA
China
DKK million
2021
2020 2019
2021
2020 2019 2021
2020
2019
2021
Rest of World
2020 2019
Total NAO
Of which the US
2021
2020 2019 2021 2020 2019
2021
2020
2019
Diabetes and Obesity care segment:
Rybelsus®
524
36
289
OzempicⓇ
Victoza®
Total GLP-1
Long-acting insulin
- of which TresibaⓇ
- of which XultophyⓇ
- of which LevemirⓇ
Premix insulin
- of which RyzodegⓇ
- of which NovoMix®
Fast-acting insulin
- of which FiaspⓇ
- of which NovoRapidⓇ
Human insulin
Total insulin
Other Diabetes care
Total Diabetes care
8,856 3,634 1,143
6,393
6,726 7,095 7,249 3,527
16,106 10,765 8,392 10,209
11,074 9,959 9,035 6,729
5,486 4,407 3,477 2,979
2,135 1,789 1,493 1,693
3,453 3,763
4,065 2,057
10,512 10,246 9,707 2,879
1,711 1,291 993 392
8,801 8,955 8,714 2,487
10,903 10,808 10,304 6,454
1,106 832 617 965
9,797 9,976 9,687 5,489 5,820 5,837
7,453 7,339 7,361 2,152 2,370 2,438
39,942 38,352 36,407 18,214 18,364 17,975
713
725 1,052
36
3,112 969 303
4,251 4,713 1,544
7,399 5,682 1,847
6,451 5,955 2,080
2,574 1,983 1,095
1,605 1,407
235
10
1,033
1,043
1,471
418
3
1
439
2,272 2,565
2,959 3,160
321 237
2,638 2,923
6,584 6,422 2,288
764 585
982
1,052
972
414
1,412 1,415 1,407
183
86
528
439
4,243 4,561 5,782
522 655 717
2,225 3,264
5,224
283
4,941 4,813
2,075
4,852
39
4,306
2,409 2,435
2,241
691
679
4
1,036 931
752
2,160 512
898 1,655 1,811
898 4,050 2,323 1,812 37,491 31,066 24,829 35,442 29,768 23,866 53,597 41,831
1,059 2,265 2,037 2,021 6,990 8,480 11,741 6,412 7,962 11,271 18,064 18,439
87
4,191 5,500 9,729 8,968
642 708 2,657 2,444
3,129 5,063 5,678
839 11,203 10,925
1,711 1,291
4,314 1,837
50 4,243 1,826
174 24,849 17,577 10,094 23,168 16,650 9,599 33,705 21,211 11,237
1,638 8,328 11,652 14,685 8,031 11,292 14,217 15,054 18,747 21,934
33,221
50
4,838 1,873
50
20,776
5,242
871
3,793
512
2,107
665
9,259
2,210
7,027
9,307
652
10,578
993
4,302
1,753
1,373 1,504 1,489
2,161 2,149 2,129
691
679
871
665
Obesity care (SaxendaⓇ and WegovyⓇ)
Diabetes and Obesity care total
2,644 2,946 3,389
58,692 52,063 48,188 29,136 26,488 24,709 15,563
981
3,117 2,118 2,083 1,809 1,124
61,809 54,181 50,271 30,945 27,612 25,690 15,624
141
32
2,288 2,075 1,753 2,020 2,081 2,097
2,692 2,655 2,847 2,609 2,314
12,284 11,053 9,965 9,444 8,935
1,432 1,546
1,647
13,642 12,510
68
6,784 7,505 8,999
642 553 626
6,142 6,952 8,373 5,752
6,357
605
519
6,582
652
7,101 8,592 17,687 18,313
597 1,748 1,385
7,995 15,939 16,928
839 9,492
9,634
9,585
19,303
1,243
18,060
2,076 1,599 1,534 1,675 1,515 1,431 1,552 9,052 8,873
9,036
499
675
8,467
690
61
10
13,652
16,064 18,198 23,286 14,949 17,146 22,254 56,006 56,550
950 1,085 858 806 943 705 3,594 4,031
13,993 11,933 10,969 54,505 50,349 48,973 51,197 47,857 46,825 113,197 102,412
9 1,247 984 1,093 5,283 3,490 3,596 4,912 3,230 3,348 8,400 5,608
12,519 15,240 12,917 12,062 59,788 53,839 52,569 56,109 51,087 50,173 121,597 108,020
59,693
4,247
97,161
5,679
102,840
Biopharm segment:
Rare blood disorders
- of which Haemophilia A
- of which Haemophilia B
- of which NovoSevenⓇ
Rare endocrine disorders
Other Biopharm
Biopharm total
5,784 5,708 5,946 3,712
1,625 1,332 1,176 1,162
400 306 197
3,673 3,996 4,502 2,225
4,880 4,832 4,225 2,212 2,220 1,960
1,064 1,108 1,122 837 886
11,728 11,648 11,293 6,761 6,685 6,518
3,579 3,646
222
361
983
877
24
16
284
15
1,850 1,768 2,016 4,433 3,954 4,335 4,170 3,675 4,031 10,217 9,662 10,281
439
333
284
487
381
382
460
268
199
149
4
128
107
48
237
212
185
102
358
86
358 2,112
77
637
1,713
1,558
518
382
2,352 2,577
194
345
269
1,254 1,299 1,656
3,548 3,207 3,617 3,461 3,089 3,454
7,221 7,203
8,119
167
66
36
2,501 2,546 2,229
912
6
5
5
395
432
325
2,423 2,875 3,052 2,400 2,857 3,037 7,303 7,707
221 217 205 619
449
501
330 205 245 1,683 1,557
4,572 4,531 4,450 7,475 7,278 7,888 6,900 6,737 7,313 19,203 18,926
7,277
1,623
19,181
Total sales by geographical area
Total sales growth as reported
73,537 65,829 61,564 37,706 34,297 32,208 16,019
11.7% 6.9% 12.1% 9.9% 6.5% 10.2% 13.7%
14,084
12,844 19,812 17,448 16,512 67,263 61,117 60,457 63,009 57,824 57,486 140,800 126,946
9.7% 13.8% 13.5% 5.7% 14.6% 10.1% 1.1% 6.2% 9.0% 0.6% 5.5% 10.9% 4.0%
122,021
9.1%View entire presentation